Aurobindo Pharma Q3 Review - Progress On New Ventures Continues: ICICI Direct 
Aurobindo Pharma Ltd.’s manufacturing line. (Image: Company website)

Aurobindo Pharma Q3 Review - Progress On New Ventures Continues: ICICI Direct 

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Aurobindo Pharma Ltd.’s revenue grew 8.0% YoY to Rs 6,365 crore led by 13.2% YoY growth in Europe formulations business to Rs 1,671 crore.

U.S. business grew 6.8% YoY to Rs 3,172 crore. Antiretroviral segment grew 41.5% YoY to Rs 443 crore. Rest of world markets posted growth of 14.5% YoY to Rs 396 crore.

However, active pharmaceutical ingredient segment de-grew 13.6% YoY to Rs 682 crore.

Ebitda margins grew 101 basis points YoY to 21.5% with higher gross margins being partly offset by higher other expenditure. Ebitda grew 13.3% YoY to Rs 1,369 crore.

Click on the attachment to read the full report:

ICICI Direct Aurobindo Pharma Q3FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.